Početna stranicaSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Preth. zaklj. cijena
10,83 $
Dnevni raspon
10,71 $ - 10,79 $
Godišnji raspon
7,27 $ - 12,00 $
Tržišna kapitalizacija
3,07 bil. JPY
Prosječna količina
117,39 tis.
P/E omjer
-
Prinos dividende
-
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (JPY) | pro 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 147,72 mlr. | 23,48 % |
Operativni troškovi | 48,45 mlr. | −3,83 % |
Neto dohodak | 74,68 mlr. | 47,39 % |
Neto profitabilnost | 50,56 | 19,36 % |
Zarada po dionici | — | — |
EBITDA | 80,21 mlr. | 36,44 % |
Efektivna porezna stopa | 19,60 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (JPY) | pro 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 215,60 mlr. | −29,45 % |
Ukupna imovina | 1,73 bil. | 13,94 % |
Ukupne obveze | 213,60 mlr. | 38,72 % |
Ukupni kapital | 1,51 bil. | — |
Dionice u optjecaju | 850,98 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,01 | — |
Povrat imovine | 11,09 % | — |
Povrat kapitala | 12,36 % | — |
Tok novca
Neto promjena novca
| (JPY) | pro 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 74,68 mlr. | 47,39 % |
Gotovina od poslovanja | 32,03 mlr. | −21,48 % |
Gotovina iz ulaganja | −26,57 mlr. | −54,23 % |
Gotovina iz financiranja | −29,20 mlr. | −17,14 % |
Neto promjena novca | −18,27 mlr. | −940,68 % |
Slobodan tok novca | −10,55 mlr. | −29.095,85 % |
Više
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Glavni izvršni direktor
Osnovano
1878
Sjedište
Web-lokacija
Zaposlenici
4.955
